🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

83 results for “KS” Clear

  1. A sterile preservative-free solution with identical composition as the drug product, but without the protein.

    Kiniksa Pharmaceuticals International, plc

    Sjögren’s Disease

    phase 2 small molecule active

    1 trial

  2. ALKS 2680, ALKS 2680, Placebo to match ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Idiopathic Hypersomnia (IH)

    phase 2 small molecule active

    1 trial

  3. Abiprubart

    Kiniksa Pharmaceuticals International, plc

    Sjögrens Disease

    phase 2 small molecule terminated

    1 trial

  4. Citanest® Dental Octapressin 30 mg/ml + 0,03 IE/ml, Xylocain ®Dental adrenalin 20 mg/ml + 12,5 mikrog/ml Injeksjonsvæske, oppløsning i sylindretter

    Lacuna Pharma Pty Ltd

    Subjects having local anesthesia for dental procedures.

    phase 2 small molecule active

    1 trial

  5. Computerized tasks

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  6. Fibromun, Darleukin

    Philogen S.p.A.

    Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)

    phase 2 small molecule active

    1 trial

  7. Folinezuur Kalceks 10 mg/ml oplossing voor injectie/infusie, Paclitaxel Fresenius Kabi 6 mg/ml concentraat voor oplossing voor infusie, Carboplatin Accord 10 mg/ml, concentraat voor oplossing voor infusie, Docetaxel Eugia 20 mg/ml, concentraat voor oplossing voor intraveneuze infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    oesophageal cancer, oesophagogastric junction cancer

    phase 2 small molecule active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion, NEMVALEUKIN ALFA, NEMVALEUKIN ALFA

    Wuhan Createrna Science and Technology Co., Ltd

    Advanced cutaneous melanoma and Advanced mucosal melanoma

    phase 2 small molecule active

    1 trial

  9. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  10. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Well-Controlled Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  11. KPL-404

    Kiniksa Pharmaceuticals International, plc

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  12. KPL-716

    Kiniksa Pharmaceuticals International, plc

    Chronic Idiopathic Urticaria

    phase 2 small molecule completed

    1 trial

  13. KPL-914

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule completed

    1 trial

  14. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Verona Pharma Ireland Limited

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial

  15. Mavrilimumab

    Kiniksa Pharmaceuticals International, plc

    COVID-19

    phase 2 small molecule completed

    3 trials

  16. Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

  17. Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 1

    phase 2 small molecule active

    1 trial

  18. SK-PC-B70M

    Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  19. Vixarelimab

    Kiniksa Pharmaceuticals International, plc

    Prurigo Nodularis

    phase 2 small molecule completed

    1 trial

  20. Workshop

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  21. ZL-1102 1% w/w gel BID for 16 weeks

    Hong Kong Baptist University

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  22. mavrilimumab

    Kiniksa Pharmaceuticals International, plc

    Giant Cell Arteritis

    phase 2 other completed

    1 trial

  23. A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists

    AstraZeneca AB

    Asthma

    phase 1 other active

    1 trial

  24. A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs are at different doses.

    Hoffmann-La Roche

    HER2-positive advanced solid tumours

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources